| Management target | Revenue 70.0% FY28 |
|---|
| Revenue growth | 15% YoY |
|---|---|
| Margins | EBITDA margin at 25%; PAT margin at 14% |
| Demand visibility | Double-digit growth expected in India for Epoxy and CPVC |
| Management confidence | Positive outlook based on India's growth |
Growth
Revenue reached ₹709 Cr (up 15% YoY); PAT rose to ₹99 Cr (up 25% YoY). EBITDA margin stood at 25%.
Outlook
Revenue from derivatives and specialty segments targeted to reach ~70% by FY28E. Major capacity expansions commissioned by H2FY28.
Risks
Geopolitical tensions in West Asia, raw material price fluctuations, elevated freight costs, and shipment delays.
Last quarter's promises, checked
Delivered
- Guided 10-12% volume growth → delivered 15% YoY revenue growth (= BEAT)
- Guided FY27 better than FY26 volume → delivered 15% revenue growth (= BEAT)
- Guided maintaining EBITDA margins → delivered 25% vs 23% prev (= BEAT)
Partly delivered
- Guided 10% volume growth → delivered 5% sales volume growth (= PARTIAL)
Investor Presentation filed with BSE, NSE: EPIGRAL. Summary written with AI assistance from the document.
Epigral Ltd: key numbers
- Share price
- ₹1,019.90
- Market cap
- ₹4,400 Cr
- Revenue (annual)
- ₹2,527 Cr
- Net profit (annual)
- ₹332.0 Cr
- P/E (TTM)
- 16.2×Sector 37.2×
- Promoter holding
- 68.83%+0.00% QoQ
- FII holding
- 1.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Epigral Ltd
All →Epigral Earnings Call Transcript: Key Takeaways
Epigral reported 15% revenue growth and 25% EBITDA margins despite Red Sea logistical disruptions. Management is pivoting toward high-value downstream specialty chemicals like Epoxy resins to reduce commodity exposure.
- Call
- Guides 20% growth
Epigral Capacity Expansion: ₹650 Cr Investment
Epigral Ltd will invest ₹650 Crore to add 1,25,000 TPA of Epoxy Resin & Formulations capacity at its Dahej facility, expected by H2 FY2028.
- Value
- ₹650.0 Cr
- Execution
- By H2 FY2028
Epigral Results Update
Epigral reported Q1FY27 PAT of ₹99 Crore, a 25% YoY increase. The company plans ₹600 Crore capex for Epoxy Resin and Multi-Purpose Plant.
- Value
- ₹600.0 Cr
- Execution
- H2FY28
Epigral Capacity Expansion: ₹600 Cr Investment
Epigral Limited plans to establish a new manufacturing facility for Epoxy Resin and Multi-Purpose Plant at Dahej, Gujarat. The project requires an investment of ₹600 Crore.
- Value
- ₹600.0 Cr
- Execution
- By H2 FY2028
Epigral Q1 FY27 Results: Net Profit ₹99.7 Cr, Down 38.0% YoY
Epigral Ltd reported revenue from operations of ₹705.4 Cr (+16.3% YoY) and net profit of ₹99.7 Cr (-38.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹99.7 Cr · -38.0% YoY
Epigral Board Meeting Date
Epigral Ltd scheduled a board meeting for July 27, 2026. The board will consider the company's first quarter unaudited financial results.